TME Therapeutics Inc.



Our aim is to develop novel therapeutics that regulate “tumor microenvironment (TME)” for the treatment of unresectable pancreatic cancer, esophageal stricture post-endoscopic therapy against esophageal cancer, etc.

Our main approach is to develop oligonucleotide compounds that inhibit the expression of several glycogenes, which are involved in tissue remodeling in various disease microenvironment including cancer and fibrosis.


dsRNA: double stranded RNA, NASH: Nonalcoholic Steatohepatitis, COPD: Chronic Obstructive Pulmonary Disease.